Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1580938 | 0.82 | TSHR (0.39) | CA2CA9TSHRALDH1A1 | |
| SCHEMBL8009753 | 0.70 | TSHR (0.58) | TSHRALDH1A1 | |
| SCHEMBL76625 | 0.69 | — | — | |
| SCHEMBL13211869 | 0.69 | — | — | |
| SCHEMBL27141 | 0.67 | — | — | |
| SCHEMBL1014584 | 0.67 | — | — | |
| SCHEMBL13284809 | 0.67 | CA2 (0.42) | CA2CA9TSHRALDH1A1 | |
| Phosphine SCHEMBL21227051 | 0.67 | CA2 (0.42) | CA2CA9TSHRALDH1A1 | |
| SCHEMBL8731771 | 0.67 | CA2 (0.42) | CA2CA9TSHRALDH1A1 | |
| SCHEMBL17052578 | 0.67 | CA2 (0.42) | CA2CA9TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748826-B2 | Radioimaging methods using teboroxime and thallium | BIOSENSOR INTERNATIONAL GROUP, LTD. (BM) | 2014-06-10 | — | — | US | disclosed |
| US-20140037541-A1 | RADIOIMAGING METHODS USING TEBOROXIME AND THALLIUM | BIOSENSOR INTERNATIONAL GROUP LTD. (BM) | 2014-02-06 | — | — | US | disclosed |
| US-8610075-B2 | Radioimaging applications of and novel formulations of teboroxime | BIOSENSORS INTERNATIONAL GROUP LTD. (BM) | 2013-12-17 | — | — | US | disclosed |
| US-8481946-B2 | — | — | 2013-07-09 | — | — | US | disclosed |
| US-20100140483-A1 | RADIOIMAGING APPLICATIONS OF AND NOVEL FORMULATIONS OF TEBOROXIME | Spectrum Dynamics Medical Limited (VG) | 2010-06-10 | — | — | US | disclosed |
| WO-2008059489-A2 | RADIOIMAGING APPLICATIONS OF AND NOVEL FORMULATIONS OF TEBOROXIME | SPECTRUM DYNAMICS LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-0199260-B1 | BORONIC ACID ADDUCTS OF TECHNETIUM-99M DIOXIME COMPLEXES | E.R. Squibb & Sons, Inc. (US) | 1989-12-06 | — | — | EP | disclosed |
| US-4705849-A | Boronic acid adducts of technetium-99m dioxime complexes | E. R. SQUIBB & SONS, INC. (US) | 1987-11-10 | — | — | US | disclosed |
| EP-0199260-A2 | Boronic acid adducts of technetium-99M dioxime complexes | E.R. Squibb & Sons, Inc. (US) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140037541-A1 | RADIOIMAGING METHODS USING TEBOROXIME AND THALLIUM | TPO, THRB, SLC6A12 | CA2 1823/4885CA9 847/4885TSHR 51/4885 |
| US-20100140483-A1 | RADIOIMAGING APPLICATIONS OF AND NOVEL FORMULATIONS OF TEBOROXIME | TNNI3, TNNT2, IDO1 | CA2 3274/4885CA9 882/4885TSHR 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.